Alumis Inc. Common Stock (ALMS)
Stock · NASDAQ · Health Care
$6.12as of 10/16/2026
Price chart
Active signals
ALMS Signal Track Record
How signals performed across all stocks →What ALMS's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 13 | +7.7% | 62% | September 1, 2026 |
| Bollinger Band Breakout | 8 | +13.9% | 75% | June 12, 2026 |
| Bollinger Band Breakdown | 7 | -7.9% | 43% | September 1, 2026 |
| Any 20-session window (baseline) | +5.4% | 57% |
Computed by MarketWall from daily closing prices since April 15, 2025. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory a…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 237
- Website
- www.alumis.com/
Fundamentals
- 1-day range
- $6.08$6.5
- Market cap
- $3.54B
- P/E (trailing)
- —
- P/E (forward)
- -2.20
- EPS (trailing)
- $-3.81
- Dividend yield
- —
- Beta
- 1.26
- Avg. volume
- 2.49M
How Alumis Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 19, 2026 · via SEC EDGAR / Finnhub
Forecasts
8 analyst ratings
Alumis Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ALMSAlumis Inc. Common Stock$6.12▼ 3.01%Market cap $3.54BP/E —$4.37$31.35
- RCUSArcus Biosciences Inc. Common Stock$22.12▼ 3.07%Market cap $3.56BP/E —$15.38$31.74
- LEGNLegend Biotech Corporation American Depositary Shares$18.48▼ 6.67%Market cap $3.58BP/E —$16.24$37.5
- IDYAIDEAYA Biosciences Inc. Common Stock$32.85▼ 2.95%Market cap $3.50BP/E —$26.44$42.68
- TLXTelix Pharmaceuticals Limited American Depositary Shares$10.69▲ 1.14%Market cap $3.60BP/E —$6.28$13.11
- ELVNEnliven Therapeutics Inc. Common Stock$37.32▼ 5.11%Market cap $3.67BP/E —$14.79$62.32
- GPCRStructure Therapeutics Inc. American Depositary Shares$21.08▼ 5.00%Market cap $3.74BP/E —$25.59$94.9
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ALMS Alumis Inc. Common Stock | $3.54B | — | $6.12 | ▼ 3.01% | $4.37$31.35 |
| RCUS Arcus Biosciences Inc. Common Stock | $3.56B | — | $22.12 | ▼ 3.07% | $15.38$31.74 |
| LEGN Legend Biotech Corporation American Depositary Shares | $3.58B | — | $18.48 | ▼ 6.67% | $16.24$37.5 |
| IDYA IDEAYA Biosciences Inc. Common Stock | $3.50B | — | $32.85 | ▼ 2.95% | $26.44$42.68 |
| TLX Telix Pharmaceuticals Limited American Depositary Shares | $3.60B | — | $10.69 | ▲ 1.14% | $6.28$13.11 |
| ELVN Enliven Therapeutics Inc. Common Stock | $3.67B | — | $37.32 | ▼ 5.11% | $14.79$62.32 |
| GPCR Structure Therapeutics Inc. American Depositary Shares | $3.74B | — | $21.08 | ▼ 5.00% | $25.59$94.9 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Srinivas Akkaraju · September 8, 2026 · Buy273.3K @ $10.63
- Srinivas Akkaraju · September 8, 2026 · Buy273.3K @ $10.63
- Srinivas Akkaraju · September 8, 2026 · Sale48.1K @ $10.55
- Srinivas Akkaraju · September 8, 2026 · Sale48.1K @ $10.55
- Srinivas Akkaraju · September 4, 2026 · Buy220.1K @ $11.17
- John R. Schroer · August 3, 2026 · Sale3.3K @ $26.37
- Roy C. Hardiman · August 3, 2026 · Sale2.7K @ $26.37
- Mark Christopher Bradley · August 3, 2026 · Sale2.6K @ $26.37
- Jorn Drappa · August 3, 2026 · Sale2.4K @ $26.37
- David M. Goldstein · August 3, 2026 · Sale2.6K @ $26.37
- Sanam Pangali · August 3, 2026 · Sale1.4K @ $26.37
- Sanam Pangali · July 6, 2026 · Option Exercise5.0K @ $5.06
- Sanam Pangali · July 6, 2026 · Sale5.0K @ $28
- Lynn A. Tetrault · June 30, 2026 · Grant15.5K
- Lynn A. Tetrault · June 30, 2026 · Grant3.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 98.24M
- Total value held
- $2.09B
- Institutional holders
- 192
- Unknown7.17M
- Unknown6.77M
- Unknown6.35M
- Unknown5.90M
- Unknown4.53M
- Unknown4.25M
- Unknown4.03M
- Unknown3.95M
- Unknown3.54M
- Unknown3.29M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
Alumis reports positive Phase 3 psoriasis data for envudeucitinib
Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.
Alumis reports positive Phase 3 psoriasis data for envudeucitinib. Alumis announced new Phase 3 results showing that its drug envudeucitinib improved scalp psoriasis, itch, and quality of life measures. The company confirmed that the New Drug Application submission is on track for the fourth quarter of 2026. While the clinical data was positive, analysts have expressed a mixed view on the immediate market impact of these results.